Drugs / ATRN-119
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07617363 | Aug 2026 → Jan 2030 expected | acute myeloid leukemia, myelodysplastic syndrome | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07578467 | Aug 2026 → May 2030 expected | human papillomavirus-related squamous cell carcinoma, oropharynx squamous cell carcinoma | Abramson Cancer Center at Penn Medicine | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT04905914 | Jan 2023 → Feb 2028 expected | neoplasm | Aprea Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATRN-119 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04905914 ↗ |
| Action | Inhibit | “an ATR Inhibitor” NCT07617363 ↗ |
| Route | Oral | “Once daily oral administration.” NCT04905914 ↗ |
| Target | ATR | “an ATR Inhibitor” NCT07617363 ↗ |